Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NDAC to discuss ipecac

This article was originally published in The Tan Sheet

Executive Summary

FDA advisory committee will consider the "safety and efficacy of ipecac syrup indicated for emergency use to cause vomiting in poisoning cases for continued OTC status" during a June 12 meeting. Primary areas of consideration will be: status of the role of ipecac syrup in gastrointestinal decontamination; whether the literature clearly defines the syrup's risk/benefit ratio; the role of ipecac in poison treatment for populations with limited access to emergency medical treatment; whether there is significant abuse of ipecac; and alternative therapies to ipecac syrup, FDA says. NDAC meeting will begin at 8 a.m. at the Holiday Inn, 8120 Wisconsin Ave., Bethesda, Md...

You may also be interested in...



Hanmi And LG Chem Highlight Vaccine Prowess, Novel R&D At JPM

Hanmi showcases at JPM its contract production capabilities for COVID-19 vaccines as South Korea prepares to bring in candidates from several global developers, while LG Chem highlights progress across multiple pipeline projects.

Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker

Vaccination Health Next Stop For Dentovations’ Self+ Immunity Supplement Line

Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.

Topics

UsernamePublicRestriction

Register

LL016481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel